


An Official Journal
of the
American Association
for
Cancer Research



Clinical Cancer Research

February 1998 • Volume 4 Number 2
PP. 265-526 • ISSN 1078-0432

AACR Annual Meeting
Advance Registration and
Housing Forms Inside

FEBRUARY 16-21, 1998

Innovative Molecular Biology Approaches to the Prevention, Diagnosis, and Therapy of Cancer

Joint Meeting with the Japanese Cancer Association
Chairpersons: Edward Bresnick, Worcester, MA;
Kaoru Abe, Tokyo, Japan
Maui Marriott Resort, Maui, HI

MARCH 28-APRIL 1, 1998

89th Annual Meeting

Chairperson: Frank J. Rauscher III, Philadelphia, PA
Morial Convention Center, New Orleans, LA

JUNE 14-18, 1998

Proteases and Protease Inhibitors in Cancer

Co-Sponsored by Acta Pathologica Microbiologica
Immunologica Scandinavica
Chairpersons: Keld Dano, Copenhagen, Denmark; and
Lynn M. Matrisian, Nashville, TN
Nyborg Strand Conference Center, Nyborg, Denmark

SEPTEMBER 24-28, 1998

Cellular Targets of Viral Carcinogenesis

Chairperson: Thea D. Tlsty, San Francisco, CA
Co-Chairpersons: Don Ganem, San Francisco, CA;
Peter M. Howley, Boston, MA; Carol L. Prives,
New York, NY; and Eileen P. White, Piscataway, NJ
Marriott's Laguna Cliffs Resort, Dana Point, CA

OCTOBER 14-18, 1998

Gene Regulation and Cancer (10th Anniversary of the AACR Special Conferences)

Chairpersons: Phillip A. Sharp, Cambridge, MA,
Jacqueline A. Lees, Cambridge, MA, and Steven L.
McKnight, Dallas, TX
The Homestead, Hot Springs, VA

NOVEMBER 11-15, 1998

Endogenous Sources of Mutations

Chairpersons: Lawrence J. Marnett, Nashville, TN;
James A. Swenberg, Chapel Hill, NC; Tomas A.
Lindahl, Herts, England
Sanibel Harbour Resort and Spa, Ft. Myers, FL

DECEMBER 2-6, 1998

New Approaches to Controlling Prostate Cancer

Moderator: Donald S. Coffey, Baltimore, MD
Chairpersons: Jonathan W. Simons, Baltimore, MD,
and Kenneth J. Pienta, Ann Arbor, MI
Hyatt Grand Champions Resort, Indian Wells (Palm
Springs), CA

JANUARY 8-12, 1999

The Steroid Receptor Superfamily

Chairpersons: M. Geoffrey Rosenfeld, La Jolla, CA;
Additional Chairperson to be Announced
Renaissance Esmeralda Resort, Indian Wells (Palm
Springs), CA

JANUARY 31-FEBRUARY 5, 1999


Cancer Biology and the Mutant Mouse: New Methods, New Models, New Insights

Chairpersons: Tyler Jacks, Cambridge, MA; Ronald A.
DePinho, New York, NY
Keystone Resort, Keystone, CO

AACR members will receive brochures on the above conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: meetings@aacr.org

For regular updates to this list visit the AACR's Website,
<http://www.aacr.org>



Clinical Cancer Research



An Official Journal
of the
American Association
for
Cancer Research

American Association for Cancer Research, Inc.

**Executive Director and
Director of Publications**
Margaret Foti

Publications Staff

Associate Director of Publications
Mary Anne Mennite

Manager, Editorial Services
Heide M. Pusztay

Staff Editors

Michael J. Beveridge
Kathleen C. Assenmacher
Pamela R. Arnold
Ronald M. Vitale

Staff Assistant

Mary Ellen Purring

Senior Editorial Assistant

Theresa A. Griffith

Editorial Assistants

Valerie L. Samuel
Cecilia Gallo

Marketing Coordinator

Robert B. O'Malley

Administrative Staff

Director of Administration
Adam D. Blistein

Controller

Joan D. Ritchie

Manager, Meetings and Exhibits

Jeffrey M. Ruben

Meeting Planner

Carole L. Kanoff

Public Information Coordinator

Jenny Anne Horst-Martz

Assistant to the Executive Director

Ruth E. Fortson

Membership Development

Coordinator

Robin E. Felder

Administrative Assistant

Margaret A. Pickels

Systems Specialist

Lydia I. Rodriguez

Secretary

Malika L. Wright

Editorial Assistant

Diana F. Certo

Office Clerk

James J. Waters

Data Entry Clerk

Robert A. Simms II

AACR Publications Department

Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Phone: (215) 440-9300
FAX: (215) 440-9354

Editor-in-Chief

John Mendelsohn

*Growth factors, hormones, cell growth;
radiation therapy, surgery, subspecialty investigation*

Deputy Editor

Waun Ki Hong

Clinical trials targeted at specific malignancies, chemoprevention

Senior Editors

Bruce A. Chabner

*Clinical pharmacology and pharmacokinetics,
drug metabolism, drug sensitivity and resistance,
drug interactions*

Michael B. Kastan

Cell cycle regulation, cell death

Lance A. Liotta

Pathology, metastasis

David Sidransky

Molecular pathogenesis, molecular correlates

Associate Editors

Martin D. Abeloff

Carmen J. Allegra

James O. Armitage

Laurence H. Baker

Charles M. Balch

Barthel Barlogie

Robert C. Bast, Jr.

Colin B. Begg

Joseph R. Bertino

Clara D. Bloomfield

Ronald H. Blum

George J. Bosl

Paul A. Bunn, Jr.

Michael A. Caligiuri

Alfred E. Chang

Paul B. Chapman

Michaë C. Christian

Curt I. Civin

Ronald Crystal

William S. Dalton

Albert B. Deisseroth

Patricia K. Donahoe

Ross C. Donehower

Timothy J. Eberlein

Merrill J. Egorin

Frederick R. Eilber

Robert M. Elashoff

Paul F. Engstrom

Eric R. Fearon

Isaiah J. Fidler

Richard M. Fox

Michael A. Friedman

Zvi Y. Fuks

Stephen L. George

Giuseppe Giaccone

Luca Gianni

Anna Giuliano

Eli Glatstein

David W. Golde

Mark R. Green

Jerome E. Groopman

William N. Hait

Adrian L. Harris

Curtis C. Harris

Sandra J. Horning

William J. Hoskins

Janet A. Houghton

Stephen B. Howell

Daniel C. Ihde

John T. Isaacs

Robert B. Jenkins

David H. Johnson

V. Craig Jordan

Barton A. Kamen

Paul Sondel

*Immunotherapy and cytokines—preclinical, and
clinical trials*

Beverly A. Teicher

*Experimental therapeutics, preclinical
pharmacology, combined modality regimens,
animal therapy models*

Jeffrey M. Trent

Genetics, cytogenetics

S. B. Kaye

David P. Kelsen

David Khayat

John M. Kirkwood

Donald W. Kufe

Steven M. Larson

John S. Lazo

Victor A. Levin

Allen Lichter

Marc E. Lippman

Edison T. Liu

Patrick J. Loehrer, Sr.

Dan L. Longo

Michael T. Lotze

Maurie Markman

William P. McGuire III

Roland Mertelsmann

Frank L. Meyskens, Jr.

John D. Minna

Monica Morrow

James L. Mulshine

Sharon B. Murphy

Charles E. Myers

Larry Norton

Richard J. O'Reilly

Robert F. Ozols

Ira Pastan

William P. Peters

Herbert M. Pinedo

Philip A. Pizzo

William K. Plunkett

Jerome B. Posner

Derek Raghavan

Mark J. Ratain

John C. Reed

Ralph A. Reisfeld

Jerome Ritz

Jack A. Roth

Eric B. Rowinsky

Edward A. Sausville

Howard I. Scher

Richard L. Schilsky

Richard M. Simon

John F. Smyth

Jeffrey A. Sosman

Michael B. Sporn

Louise C. Strong

Masaaki Terada

Daniel D. Von Hoff

Raymond P. Warrell, Jr.

Jane Weeks

Ralph R. Weichselbaum

Theresa L. Whiteside

Leonard A. Zwelling

Editorial Office

Colleen M. Hubona, *Executive Editor*, Department of Educational Publishing Services—227, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030. Phone: (713) 792-6014; Fax: (713) 792-6016.

Accelerated mailing of all AACR journals to AACR members in Japan is supported by a generous grant from the Banyu Pharmaceutical Company, Tsukuba, Japan. One-year subscriptions to *Clinical Cancer Research* are made available to third-year hematology/oncology fellows in the United States through the generous support of Rhône-Poulenc Rorer Oncology.

Clinical Cancer Research is published monthly, one volume per year, by the American Association for Cancer Research, Inc. (AACR). Except for members of the AACR, all subscriptions are payable in advance to AACR, Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Phone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588], to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsutsumi Bldg., 13-12, Shimbashi 1-chome, Minato-ku, Tokyo 105, Japan; Tel. (03) 502-6471. Individuals who are not AACR members may subscribe to Volume 4 (1998) of *Clinical Cancer Research* at the rate of \$120 U.S./\$160 foreign. *Clinical Cancer Research* is only available to institutions as a combined subscription with *Cancer Research*. The combined 1998 institutional subscription price of \$795 U.S./\$925 foreign includes \$210 U.S./\$250 foreign for a subscription to *Clinical Cancer Research*. (Foreign subscription cost includes cost of surface mail. For faster delivery, expedited mailing rates are available by contacting the AACR Publications Department.) Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: AACR Member Services, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copies of the journal which are undeliverable because of address changes will be destroyed.



R5SQ-2XH-FPE4



Notice to Members of the American Association for Cancer Research (AACR)

Officers for 1997-1998

President: Donald S. Coffey, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2101

President-Elect: Webster K. Cavenee, Ludwig Institute for Cancer Research, La Jolla, CA 92093-0660

Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 826, Philadelphia, PA 19106-3483

Annual Dues

The annual dues of active members of the AACR are \$175, \$50 of which may be applied to a subscription to *Clinical Cancer Research*. Corresponding members of the Association will be charged an appropriate fee to offset periodicals postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Phone: (215) 440-9300; FAX: (215) 440-9313.

Submission of Manuscripts

Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. *Clinical Cancer Research* is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients. All submissions undergo peer review. Papers should be sent directly to an appropriate Senior Editor or to the Editor-in-Chief for review. See "Instructions for Authors" (page ii of this issue) for complete mailing addresses of the Editor-in-Chief, Deputy Editor, and Senior Editors.

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Phone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588]. As long as supplies permit, single copies will be sold by this company at \$25.00/copy. Orders outside the U.S. add \$3/copy to offset postage costs.

Advertisements

Advertisement insertion orders and copy must be received one month prior to the date of issue in which the advertisement is to be published. The journal is mailed on approximately the 1st day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Ave., Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Copyright and Permissions

Authors who wish to publish in *Clinical Cancer Research* must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer copyright to the American Association for

Cancer Research, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AACR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors *before* corresponding with the AACR.

Those who wish to photocopy articles should contact the AACR Publications Department [Phone: (215) 440-9300; FAX: (215) 440-9354].

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Clinical Cancer Research is abstracted and/or indexed in *Cancer Lit*, *Chemical Abstracts*, and *Current Contents (Clinical Medicine)*.

Clinical Cancer Research (ISSN 1078-0432) is published monthly by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for \$50 annually for members and \$120 for individual nonmembers. *Clinical Cancer Research* is only available to institutions as a combined subscription with *Cancer Research*. The combined 1998 institutional subscription price of \$795 includes \$210 for a subscription to *Clinical Cancer Research*. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copyright 1998 by the American Association for Cancer Research, Inc. Printed on acid-free paper in the U.S.A.

- 407 Prognostic Value of $\alpha 6\beta 4$ Integrin Expression in Breast Carcinomas Is Affected by Laminin Production from Tumor Cells.** Elda Tagliabue, Cristina Ghirelli, Paolo Squicciarini, Pierangela Aiello, Maria Ines Colnaghi, and Sylvie Ménard.
- 411 Assessment of Messenger RNA of $\beta 1 \rightarrow 4$ -N-Acetylgalactosaminyltransferase as a Molecular Marker for Metastatic Melanoma.** Christine T. Kuo, Peter J. Bostick, Reiko F. Irie, Donald L. Morton, Andrew J. Conrad, and Dave S. B. Hoon.
- 419 Prognostic Significance of Peripheral Blood and Bone Marrow Tyrosinase Messenger RNA in Malignant Melanoma.** Ronald A. Ghossein, Daniel Coit, Murray Brennan, Zuo Feng Zhang, Yan Wang, Satyajit Bhattacharya, Alan Houghton, and Juan Rosai.
- 429 Significance of Platelet-derived Endothelial Cell Growth Factor in the Angiogenesis of Human Gastric Cancer.** Yutaka Takahashi, Corazon D. Bucana, Yoshito Akagi, Wenbiao Liu, Karen R. Cleary, Masayoshi Mai, and Lee M. Ellis.
- 435 Careful Histological Confirmation and Microdissection Reveal Telomerase Activity in Otherwise Telomerase-negative Breast Cancers.** Lisa A. Carey, Catigan A. Hedican, Gregory S. Henderson, Christopher B. Umbricht, Jeffrey S. Dome, Debora Varon, and Saraswati Sukumar.
- 441 A Comparison between Microsatellite and Quantitative PCR Analyses to Detect Frequent *p16* Copy Number Changes in Primary Bladder Tumors.** John Paul Cairns, Pei-Wen Chiang, Saravanan Ramamoorthy, David M. Kurnit, and David Sidransky.
- 445 Sequential Treatment of Human Chronic Lymphocytic Leukemia with Bryostatin 1 followed by 2-Chlorodeoxyadenosine: Preclinical Studies.** Ramzi M. Mohammad, Khalil Katato, Victor P. Almatchy, Nathan Wall, Kan-zhi Liu, Christian P. Schultz, Henry H. Mantsch, Mary Varterasian, and Ayad M. Al-Katib.
- 455 Altered Irinotecan and SN-38 Disposition after Intravenous and Oral Administration of Irinotecan in Mice Bearing Human Neuroblastoma Xenografts.** William C. Zamboni, Peter J. Houghton, Joyce Thompson, Pamela J. Cheshire, Suzan K. Hanna, Lois B. Richmond, Xiaolong Lou, and Clinton F. Stewart.
- 463 Activity of Fotemustine in Medulloblastoma and Malignant Glioma Xenografts in Relation to *O*⁶-Alkylguanine-DNA Alkyltransferase and Alkylpurine-DNA *N*-Glycosylase Activity.** Gilles Vassal, Isabelle Boland, Marie-José Terrier-Lacombe, Amanda J. Watson, Geoffrey P. Margison, Anne-Marie Vénuat, Jackie Morizet, Fabrice Parker, Catherine Lacroix, Arielle Lellouch-Tubiana, Alain Pierre-Kahn, Marie Gwenaëlle Poullain, and Alain Gouyette.
- 469 Pretreatment of Colon Carcinoma Cells with Tomudex Enhances 5-Fluorouracil Cytotoxicity.** Giuseppe S. A. Longo, Julie Izzo, Yu Ming Chang, William P. Tong, Zbigniew Zielinski, Richard Gorlick, Ting-Chao Chou, and Joseph R. Bertino.
- 475 Heterogeneity of *O*⁶-Alkylguanine-DNA-alkyltransferase Measured by Flow Cytometric Analysis in Blood and Bone Marrow Mononuclear Cells.** Lili Liu, Keunmyoung Lee, Jane Schupp, Omer N. Koc, and Stanton L. Gerson.
- 483 Acute *in Vivo* Resistance in High-Dose Therapy.** Beverly A. Teicher, Gulshan Ara, Susan R. Keyes, Roy S. Herbst, and Emil Frei III.
- 493 High Susceptibility of Human Cancer Xenografts with Higher Levels of Cytidine Deaminase to a 2'-Deoxycytidine Antimetabolite, 2'-Deoxy-2'-methylidenecytidine.** Masanori Miwa, Hiroyuki Eda, Masako Ura, Kaori F. Ouchi, Dennis D. Keith, Louise H. Foley, and Hideo Ishitsuka.
- 499 Comparative Study of the Antitumor Activity of Free Doxorubicin and Polyethylene Glycol-coated Liposomal Doxorubicin in a Mouse Lymphoma Model.** Anna Cabanes, Dinah Tzemach, Dorit Goren, Aviva T. Horowitz, and Alberto Gabizon.
- 507 Phagocytosis of Cross-Linked Gelatin Matrix by Human Breast Carcinoma Cells Correlates with Their Invasive Capacity.** Peter J. Coopman, Michael T. H. Do, Erik W. Thompson, and Susette C. Mueller.
- 517 *bcl-2*, *bax*, *bcl-x_L*, and *bcl-x_s* Expression in Normal and Neoplastic Ovarian Tissues.** Maria Marone, Giovanni Scambia, Simona Mozzetti, Gabriella Ferrandina, Sonia Iacovella, Anna De Pasqua, Pierluigi Benedetti-Panici, and Salvatore Mancuso.
-
- 525 AACR Bulletin Board**
Institution of Page Charges
Annual Meeting
Late-Breaking Research Session at the AACR Annual Meeting
Workshop on Molecular Biology in Clinical Oncology
AACR Special Conferences in Cancer Research
- 526 Author Index**
- i Instructions for Authors**

1998 AACR Annual Meeting

March 28–April 1, 1998
New Orleans, LA

For complete information about the meeting, visit the AACR Website at

<http://www.aacr.org>

**National Cancer Institute
Division of Clinical Sciences
Bethesda, Maryland**

Opening Date: January 21, 1998

Closing Date: March 31, 1998

Announcement Number: CA-97-0335

Chief, Radiation Oncology Branch

The Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, is seeking applicants for the position of the Chief of the Radiation Oncology Branch. The Branch Chief is responsible for directing the clinical and laboratory research programs in the areas of radiation therapy, radiation medicine, radiation physics, radiation biology, and radioimmune and inorganic chemistry. This position involves conducting clinical and laboratory studies; supervising junior investigators and co-leading a coordinated residency training program in radiation oncology which encompasses patient populations from the National Institutes of Health, the National Naval Medical Center, and the Walter Reed Army Medical Center. Moreover, the Chief of the Radiation Oncology Branch will be the primary spokesperson for the Division of Clinical Sciences for matters pertaining to radiation oncology. The Radiation Oncology Branch has an operating budget of \$6.4 million, 16,000 square feet of laboratory, clinic and office space, and a staff of approximately 65 scientific and support personnel.

This is a civil service position with an annual salary range of \$150,000 to \$200,000 depending upon the applicant's qualifications.

All applications should include the following: A letter expressing interest in the position; a statement of research interest; a career synopsis and brief bibliography; a current curriculum vitae and complete bibliography; and the names and addresses of five references. A list of the requirements or additional information about the position may be obtained by contacting Ms. Debbie Breedlove at the address listed below.

Applications should be sent to:

Ms. Debbie Breedlove
Administrative Resource Center 31
National Cancer Institute
National Institutes of Health
Building 31, Room 3A20
31 Center Drive—MSC 2440
Bethesda, Maryland 20892-2440
Telephone: (301) 402-5736
FAX: (301) 480-0215

Selection for this position will be based solely on merit with no discrimination for non-merit reasons such as race, color, gender, national origin, age, religion, sexual orientation, or physical or mental disability

NIH IS AN EQUAL OPPORTUNITY EMPLOYER

AMERICAN CANCER SOCIETY CLINICAL RESEARCH TRAINING GRANT FOR JUNIOR FACULTY

The American Cancer Society is pleased to announce the Clinical Research Training Grant for Junior Faculty (CRTG). This award is intended to provide the resources for junior faculty members to achieve the mentored research training and experience required for successful careers as independent clinical researchers. The purpose of this grant is to support clinical research by individuals with doctoral or equivalent degrees who are not yet fully independent investigators. Through the CRTG, the Society hopes that this program will develop clinical researchers who should then be eligible to apply for the Society's Research Project Grants as independent beginning investigators.

Candidates for first year Clinical Research Training Grants must be within the first four years of a faculty appointment in their discipline. These awards are intended to support the early development of academic careers which place emphasis on clinical research; individuals with well established careers and substantial research funding should not apply. In addition, candidates for these awards must be citizens or non-citizen nationals of the United States or its possessions or territories, or must have been lawfully admitted to the United States for permanent residence at the time of the application.

This grant provides up to \$150,000 per year including indirect costs for a period of one to three years. During the third year, recipients of this grant may apply for a one or two year competitive renewal provided the total time of clinical research training support, irrespective of the source, does not exceed five years. The next application deadlines are March 1, 1998, and October 1, 1998, for awards to begin January 1, 1999, and July 1, 1999, respectively.

To obtain further information or application materials, please contact your local grants administration office. If you are unsure whether your institution received these materials, please contact us at 404-329-7558 or -5734 (voice), 404-321-4669 (fax), or grants@cancer.org (E-mail); we will be happy to provide you with the name of your institutional contact. You may also download an IBM or Macintosh version of these materials from the Society's home page on the World Wide Web at <http://www.cancer.org>.